1
|
Paudel S, Apostolakos I, Vougat Ngom R, Tilli G, de Carvalho Ferreira HC, Piccirillo A. A systematic review and meta-analysis on the efficacy of vaccination against colibacillosis in broiler production. PLoS One 2024; 19:e0301029. [PMID: 38517875 PMCID: PMC10959377 DOI: 10.1371/journal.pone.0301029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 03/08/2024] [Indexed: 03/24/2024] Open
Abstract
Colibacillosis, a disease caused by Escherichia coli in broiler chickens has serious implications on food safety, security, and economic sustainability. Antibiotics are required for treating the disease, while vaccination and biosecurity are used for its prevention. This systematic review and meta-analysis, conducted under the COST Action CA18217-European Network for Optimization of Veterinary Antimicrobial Treatment (ENOVAT), aimed to assess the efficacy of E. coli vaccination in broiler production and provide evidence-based recommendations. A comprehensive search of bibliographic databases, including, PubMed, CAB Abstracts, Web of Science and Agricola, yielded 2,722 articles. Following a defined protocol, 39 studies were selected for data extraction. Most of the studies were experimental infection trials, with only three field studies identified, underscoring the need for more field-based research. The selected studies reported various types of vaccines, including killed (n = 5), subunit (n = 8), outer membrane vesicles/protein-based (n = 4), live/live-attenuated (n = 16), and CpG oligodeoxynucleotides (ODN) (n = 6) vaccines. The risk of bias assessment revealed that a significant proportion of studies reporting mortality (92.3%) or feed conversion ratio (94.8%) as outcomes, had "unclear" regarding bias. The meta-analysis, focused on live-attenuated and CpG ODN vaccines, demonstrated a significant trend favoring both vaccination types in reducing mortality. However, the review also highlighted the challenges in reproducing colibacillosis in experimental setups, due to considerable variation in challenge models involving different routes of infection, predisposing factors, and challenge doses. This highlights the need for standardizing the challenge model to facilitate comparisons between studies and ensure consistent evaluation of vaccine candidates. While progress has been made in the development of E. coli vaccines for broilers, further research is needed to address concerns such as limited heterologous protection, practicability for application, evaluation of efficacy in field conditions and adoption of novel approaches.
Collapse
Affiliation(s)
- Surya Paudel
- Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR
- Clinic for Poultry and Fish Medicine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Ilias Apostolakos
- Veterinary Research Institute, Hellenic Agricultural Organization “DIMITRA”, Thessaloniki, Greece
| | - Ronald Vougat Ngom
- Department of Animal Production, School of Veterinary Medicine and Sciences, University of Ngaoundere, Ngaoundéré, Cameroon
- Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Giuditta Tilli
- Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Italy
| | | | - Alessandra Piccirillo
- Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Italy
| |
Collapse
|
2
|
Abstract
The different technology platforms used to make poultry vaccines are reviewed. Vaccines based on classical technologies are either live attenuated or inactivated vaccines. Genetic engineering is applied to design by deletion, mutation, insertion, or chimerization, genetically modified target microorganisms that are used either as live or inactivated vaccines. Other vaccine platforms are based on one or a few genes of the target pathogen agent coding for proteins that can induce a protective immune response ("protective genes"). These genes can be expressed in vitro to produce subunit vaccines. Alternatively, vectors carrying these genes in their genome or nucleic acid-based vaccines will induce protection by in vivo expression of these genes in the vaccinated host. Properties of these different types of vaccines, including advantages and limitations, are reviewed, focusing mainly on vaccines targeting viral diseases and on technologies that succeeded in market authorization.
Collapse
|
3
|
Islam MS, Rahman MT. A Comprehensive Review on Bacterial Vaccines Combating Antimicrobial Resistance in Poultry. Vaccines (Basel) 2023; 11:vaccines11030616. [PMID: 36992200 DOI: 10.3390/vaccines11030616] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/03/2023] [Accepted: 03/07/2023] [Indexed: 03/11/2023] Open
Abstract
Bacterial vaccines have become a crucial tool in combating antimicrobial resistance (AMR) in poultry. The overuse and misuse of antibiotics in poultry farming have led to the development of AMR, which is a growing public health concern. Bacterial vaccines are alternative methods for controlling bacterial diseases in poultry, reducing the need for antibiotics and improving animal welfare. These vaccines come in different forms including live attenuated, killed, and recombinant vaccines, and they work by stimulating the immune system to produce a specific response to the target bacteria. There are many advantages to using bacterial vaccines in poultry, including reduced use of antibiotics, improved animal welfare, and increased profitability. However, there are also limitations such as vaccine efficacy and availability. The use of bacterial vaccines in poultry is regulated by various governmental bodies and there are economic considerations to be taken into account, including costs and return on investment. The future prospects for bacterial vaccines in poultry are promising, with advancements in genetic engineering and vaccine formulation, and they have the potential to improve the sustainability of the poultry industry. In conclusion, bacterial vaccines are essential in combating AMR in poultry and represent a crucial step towards a more sustainable and responsible approach to poultry farming.
Collapse
Affiliation(s)
- Md Saiful Islam
- Department of Microbiology and Hygiene, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
| | - Md Tanvir Rahman
- Department of Microbiology and Hygiene, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
| |
Collapse
|
4
|
Aerosol delivered irradiated Escherichia coli confers serotype-independent protection and prevents colibacillosis in young chickens. Vaccine 2023; 41:1342-1353. [PMID: 36642629 DOI: 10.1016/j.vaccine.2022.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 10/30/2022] [Accepted: 12/03/2022] [Indexed: 01/14/2023]
Abstract
Escherichia coli causes colibacillosis in chickens, which has severe economic and public health consequences. For the first time, we investigated the efficacy of gamma-irradiated E. coli to prevent colibacillosis in chickens considering different strains and application routes. Electron microscopy, alamarBlue assay and matrix assisted laser desorption/ionization time-of- flight mass spectrometry showed that the cellular structure, metabolic activity and protein profiles of irradiated and non-treated E. coli PA14/17480/5-ovary (serotype O1:K1) were similar. Subsequently, three animal trials were performed using the irradiated E. coli and clinical signs, pathological lesions and bacterial colonization in systemic organs were assessed. In the first animal trial, the irradiated E. coli PA14/17480/5-ovary administered at 7 and 21 days of age via aerosol and oculonasal routes, respectively, prevented the occurrence of lesions and systemic bacterial spread after homologous challenge, as efficient as live infection or formalin-killed cells. In the second trial, a single aerosol application of the same irradiated strain in one-day old chickens was efficacious against challenges with a homologous or a heterologous strain (undefined serotype). The aerosol application elicited better protection as compared to oculonasal route. Finally, in the third trial, efficacy against E. coli PA15/19103-3 (serotype O78:K80) was shown. Additionally, previous results of homologous protection were reconfirmed. The irradiated PA15/19103-3 strain, which also showed lower metabolic activity, was less preferred even for the homologous protection, underlining the importance of the vaccine strain. In all the trials, the irradiated E. coli did not provoke antibody response indicating the importance of innate or cell mediated immunity for protection. In conclusion, this proof-of-concept study showed that the non-adjuvanted single aerosol application of irradiated "killed but metabolically active" E. coli provided promising results to prevent colibacillosis in chickens at an early stage of life. The findings open new avenues for vaccine production with E. coli in chickens using irradiation technology.
Collapse
|
5
|
Pokharel P, Dhakal S, Dozois CM. The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen. Microorganisms 2023; 11:344. [PMID: 36838308 PMCID: PMC9965155 DOI: 10.3390/microorganisms11020344] [Citation(s) in RCA: 27] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2023] [Revised: 01/24/2023] [Accepted: 01/25/2023] [Indexed: 02/03/2023] Open
Abstract
Escherichia coli (E. coli) is a gram-negative bacillus and resident of the normal intestinal microbiota. However, some E. coli strains can cause diseases in humans, other mammals and birds ranging from intestinal infections, for example, diarrhea and dysentery, to extraintestinal infections, such as urinary tract infections, respiratory tract infections, meningitis, and sepsis. In terms of morbidity and mortality, pathogenic E. coli has a great impact on public health, with an economic cost of several billion dollars annually worldwide. Antibiotics are not usually used as first-line treatment for diarrheal illness caused by E. coli and in the case of bloody diarrhea, antibiotics are avoided due to the increased risk of hemolytic uremic syndrome. On the other hand, extraintestinal infections are treated with various antibiotics depending on the site of infection and susceptibility testing. Several alarming papers concerning the rising antibiotic resistance rates in E. coli strains have been published. The silent pandemic of multidrug-resistant bacteria including pathogenic E. coli that have become more difficult to treat favored prophylactic approaches such as E. coli vaccines. This review provides an overview of the pathogenesis of different pathotypes of E. coli, the virulence factors involved and updates on the major aspects of vaccine development against different E. coli pathotypes.
Collapse
Affiliation(s)
- Pravil Pokharel
- Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique (INRS), 531 Boul des Prairies, Laval, QC H7V 1B7, Canada
- Centre de Recherche en Infectiologie Porcine et Avicole (CRIPA), Faculté de Médecine Vétérinaire, Université de Montréal Saint-Hyacinthe, Saint-Hyacinthe, QC J2S 2M2, Canada
| | - Sabin Dhakal
- Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique (INRS), 531 Boul des Prairies, Laval, QC H7V 1B7, Canada
- Centre de Recherche en Infectiologie Porcine et Avicole (CRIPA), Faculté de Médecine Vétérinaire, Université de Montréal Saint-Hyacinthe, Saint-Hyacinthe, QC J2S 2M2, Canada
| | - Charles M. Dozois
- Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique (INRS), 531 Boul des Prairies, Laval, QC H7V 1B7, Canada
- Centre de Recherche en Infectiologie Porcine et Avicole (CRIPA), Faculté de Médecine Vétérinaire, Université de Montréal Saint-Hyacinthe, Saint-Hyacinthe, QC J2S 2M2, Canada
- Pasteur Network, Laval, QC H7V 1B7, Canada
| |
Collapse
|
6
|
Leurs K, Goossens E, Christensen H, Mainil JG, Vancraeynest D, Ducatelle R, Van Immerseel F. Development of a duplex qPCR for the differentiation of a live attenuated Escherichia coli aroA mutant vaccine strain from field isolates in chickens. PLoS One 2022; 17:e0278949. [PMID: 36534672 PMCID: PMC9762556 DOI: 10.1371/journal.pone.0278949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 11/24/2022] [Indexed: 12/24/2022] Open
Abstract
Avian pathogenic Escherichia coli (APEC) can cause colibacillosis in poultry, characterised by localised or systemic infections. Colibacillosis is considered one of the leading causes of economic losses in the poultry industry due to reduced performance, increased mortality, treatment costs and carcass condemnations. A live attenuated Escherichia coli O78 aroA gene mutant is widely used to prevent disease. However, no effective strategies to differentiate the vaccine strain from field strains are available, hampering follow-up of vaccination campaigns. In the current study, we report a PCR-based method to simultaneously detect the vaccine strain by targeting the vaccine-specific mutation in the aroA gene, as well as the wild type E. coli strains by targeting the xanQ gene. The specificity of this PCR was evaluated using 123 E. coli isolates, form which 5 WT aroA auxotrophic strains (WT strains with a natural aroA deficiency), as well as 7 non-Escherichia isolates. The PCR showed 100% sensitivity of the xanQ primers for E. coli detection and 100% sensitivity of the ΔaroA primers for the vaccine strain. In order to allow quantification of the vaccine strain in complex samples containing many different E. coli strains and other related organisms, such as chicken faeces, a probe-based duplex qPCR was developed. The limit of detection (LOD) of this duplex qPCR method was 8.4*103 copies/g faeces. The specificity of the duplex qPCR was confirmed by determining both the vaccine strain levels, and the total E. coli load in intestinal digesta from both vaccinated and non-vaccinated birds. E. coli could be detected in both vaccinated and non-vaccinated birds. The duplex qPCR was specific for the vaccine strain as this strain was detected in all vaccinated birds, whereas no signal was detected in non-vaccinated birds. The duplex qPCR is helpful in monitoring colonization and shedding of the vaccine strain.
Collapse
Affiliation(s)
- Kirsten Leurs
- Department of Pathobiology, Livestock Gut Health Team (LiGHT) Ghent, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Evy Goossens
- Department of Pathobiology, Livestock Gut Health Team (LiGHT) Ghent, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Henrik Christensen
- Department of Veterinary Microbiology, Royal Veterinary and Agricultural University, Frederiksberg C, Denmark
| | - Jacques G. Mainil
- Bacteriology Department of Infectious Diseases, Faculty of Veterinary Medicine, Centre for Fundamental and Applied Research in Animals and Health (FARAH), University of Liège (ULiège), Liège, Belgium
| | | | - Richard Ducatelle
- Department of Pathobiology, Livestock Gut Health Team (LiGHT) Ghent, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
| | - Filip Van Immerseel
- Department of Pathobiology, Livestock Gut Health Team (LiGHT) Ghent, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
- * E-mail:
| |
Collapse
|
7
|
Emergence and spread of antibiotic-resistant foodborne pathogens from farm to table. Food Sci Biotechnol 2022; 31:1481-1499. [PMID: 36065433 PMCID: PMC9435411 DOI: 10.1007/s10068-022-01157-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 07/26/2022] [Accepted: 08/17/2022] [Indexed: 11/13/2022] Open
Abstract
Antibiotics have been overused and misused for preventive and therapeutic purposes. Specifically, antibiotics are frequently used as growth promoters for improving productivity and performance of food-producing animals such as pigs, cattle, and poultry. The increasing use of antibiotics has been of great concern worldwide due to the emergence of antibiotic resistant bacteria. Food-producing animals are considered reservoirs for antibiotic resistance genes (ARGs) and residual antibiotics that transfer from the farm through the table. The accumulation of residual antibiotics can lead to additional antibiotic resistance in bacteria. Therefore, this review evaluates the risk of carriage and spread of antibiotic resistance through food chain and the potential impact of antibiotic use in food-producing animals on food safety. This review also includes in-depth discussion of promising antibiotic alternatives such as vaccines, immune modulators, phytochemicals, antimicrobial peptides, probiotics, and bacteriophages.
Collapse
|
8
|
Keita A, Le Devendec L, Amelot M, Puterflam J, Lucas C, Bougeard S, Delannoy S, Schouler C, Fach P, Lucas P, Souillard R, Kempf I. Efficacy of passive immunization in broiler chicks via an inactivated Escherichia coli autogenous vaccine administered to broiler breeder hens. Avian Pathol 2022; 51:445-456. [DOI: 10.1080/03079457.2022.2084362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Alassane Keita
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | - Laetitia Le Devendec
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | - Michel Amelot
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | | | - Camille Lucas
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | - Stéphanie Bougeard
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | - Sabine Delannoy
- ANSES – French Agency for Food, Environmental and Occupational Health and Safety Food Research Laboratory, Platform IdentyPath, 94700 Maisons-Alfort, France
| | | | - Patrick Fach
- ANSES – French Agency for Food, Environmental and Occupational Health and Safety Food Research Laboratory, Platform IdentyPath, 94700 Maisons-Alfort, France
| | - Pierrick Lucas
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | - Rozenn Souillard
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| | - Isabelle Kempf
- Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France
| |
Collapse
|
9
|
Tarabees R, El-Sayed MS, Shehata AA, Diab MS. Effects of the Probiotic Candidate E. faecalis-1, the Poulvac E. coli Vaccine, and their Combination on Growth Performance, Caecal Microbial Composition, Immune Response, and Protection against E. coli O78 Challenge in Broiler Chickens. Probiotics Antimicrob Proteins 2021; 12:860-872. [PMID: 31650414 DOI: 10.1007/s12602-019-09588-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The present study was performed on 180-day-old commercial Cobb chicks to assess the effects of the probiotic candidate Enterococcus faecalis-1, the Poulvac Escherichia coli vaccine, and their combination on growth parameters, intestinal microbial composition, immune response, and protection against challenge with the avian pathogen E. coli O78. The experimental groups were as follows: G1, basal diet; G2, basal diet and challenge with O78 at 28 days of growth; G3, basal diet, vaccination with Poulvac (1 and 15 days), and challenge with O78 at 28 days of growth; G4, basal diet, E. faecalis-1 supplementation for the first 3 days of growth, and challenge with O78 at 28 days of growth; G5, basal diet, E. faecalis-1 supplementation for the first 3 days of growth, vaccination with Poulvac (1 and 15 days), and challenge with O78 at 28 days of growth; G6, basal diet and E. faecalis-1 supplementation for the first 3 days of growth. The results showed that E. faecalis-1 in drinking water significantly improved the growth performance and immune response, increased the total Enterococcus counts, reduced the mortality, and decreased the visceral invasion by O78 in challenged broilers. While the effect of the Poulvac vaccine alone or with E. faecalis-1 was not significant compared with that of the E. faecalis-1 supplement, the vaccine improved the growth rate and decreased the mortality and visceral invasion by APEC O78 in challenged broilers. These results showed that E. faecalis-1 supplementation and routine vaccination with the Poulvac vaccine could improve the growth performance and immune response of broiler chickens and protect against challenge with APEC O78.
Collapse
Affiliation(s)
- Reda Tarabees
- Department of Bacteriology, Mycology, and Immunology, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt.
| | - Mohamed S El-Sayed
- Department of Bacteriology, Mycology, and Immunology, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt
| | - Awad A Shehata
- Department of Birds and Rabbit Diseases, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, Egypt.,Faculty of Veterinary Medicine, Albrecht-Daniel-Thaer-Institute, University of Leipzig, Leipzig, Germany
| | - Mohamed S Diab
- Department of Animal Hygiene and Zoonoses, Faculty of Veterinary Medicine, New Valley University, New Valley Governorate, Egypt
| |
Collapse
|
10
|
Swelum AA, Elbestawy AR, El-Saadony MT, Hussein EOS, Alhotan R, Suliman GM, Taha AE, Ba-Awadh H, El-Tarabily KA, Abd El-Hack ME. Ways to minimize bacterial infections, with special reference to Escherichia coli, to cope with the first-week mortality in chicks: an updated overview. Poult Sci 2021; 100:101039. [PMID: 33752065 PMCID: PMC8010699 DOI: 10.1016/j.psj.2021.101039] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 01/06/2021] [Accepted: 01/19/2021] [Indexed: 11/17/2022] Open
Abstract
On the commercial level, the poultry industry strives to find new techniques to combat bird's infection. During the first week, mortality rate increases in birds because of several bacterial infections of about ten bacterial species, especially colisepticemia. This affects the flock production, uniformity, and suitability for slaughter because of chronic infections. Escherichia coli (E. coli) causes various disease syndromes in poultry, including yolk sac infection (omphalitis), respiratory tract infection, and septicemia. The E. coli infections in the neonatal poultry are being characterized by septicemia. The acute septicemia may cause death, while the subacute form could be characterized through pericarditis, airsacculitis, and perihepatitis. Many E. coli isolates are commonly isolated from commercial broiler chickens as serogroups O1, O2, and O78. Although prophylactic antibiotics were used to control mortality associated with bacterial infections of neonatal poultry in the past, the commercial poultry industry is searching for alternatives. This is because of the consumer's demand for reduced antibiotic-resistant bacteria. Despite the vast and rapid development in vaccine technologies against common chicken infectious diseases, no antibiotic alternatives are commercially available to prevent bacterial infections of neonatal chicks. Recent research confirmed the utility of probiotics to improve the health of neonatal poultry. However, probiotics were not efficacious to minimize death and clinical signs associated with neonatal chicks' bacterial infections. This review focuses on the causes of the increased mortality in broiler chicks during the first week of age and the methods used to minimize death.
Collapse
Affiliation(s)
- Ayman A Swelum
- Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia; Department of Theriogenology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.
| | - Ahmed R Elbestawy
- Poultry and Fish Diseases Department, Faculty of Veterinary Medicine, Damanhour University, El Beheira 22511, Egypt
| | - Mohamed T El-Saadony
- Department of Agricultural Microbiology, Faculty of Agriculture, Zagazig University, Zagazig 44511, Egypt
| | - Elsayed O S Hussein
- Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia
| | - Rashed Alhotan
- Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia
| | - Gamaleldin M Suliman
- Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia
| | - Ayman E Taha
- Department of Animal Husbandry and Animal Wealth Development, Faculty of Veterinary Medicine, Alexandria University, Edfina 22578, Egypt
| | - Hani Ba-Awadh
- Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia
| | - Khaled A El-Tarabily
- Department of Biology, College of Science, United Arab Emirates University, Al-Ain 15551, United Arab Emirates; Harry Butler Institute, Murdoch University, Murdoch, 6150, Western Australia, Australia
| | - Mohamed E Abd El-Hack
- Department of Poultry, Faculty of Agriculture, Zagazig University, Zagazig 44511, Egypt
| |
Collapse
|
11
|
Christensen H, Bachmeier J, Bisgaard M. New strategies to prevent and control avian pathogenic Escherichia coli (APEC). Avian Pathol 2021; 50:370-381. [PMID: 33146543 DOI: 10.1080/03079457.2020.1845300] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Avian pathogenic Escherichia coli (APEC) infections are associated with major economical losses and decreased animal welfare. In broiler production, APEC infections have traditionally been controlled by antibiotics, resulting in an increased prevalence of antibiotic-resistant E. coli. Concerns have been raised that transfer of antibiotic-resistant APEC via the food chain may result in risks for extra-intestinal infection of humans related to zoonotic transfer and increased difficulties in the treatment of human infections caused APEC-related E. coli types. In this review, the risks associated with APEC are presented based on new knowledge on transmission, virulence and antibiotic resistance of APEC. A major new change in our understanding of APEC is the high degree of genuine vertical transfer of APEC from parents to offspring. A new strategy for controlling APEC, including control of antibiotic-resistant APEC, has to focus on limiting vertical transfer from parents to offspring, and subsequent horizontal transmission within and between flocks and farms, by using all-in-all-out production systems and implementing a high level of biosecurity. Vaccination and the use of competitive exclusion are important tools to be considered. A specific reduction of antibiotic-resistant APEC can be obtained by implementing culling strategies, only allowing the use of antibiotics in cases where animal welfare is threatened. Strategies to reduce APEC, including antibiotic-resistant APEC, need to be implemented in the whole production pyramid, but it has to start at the very top of the production pyramid.
Collapse
Affiliation(s)
- Henrik Christensen
- Department of Veterinary and Animal Sciences, University of Copenhagen, Copenhagen, Denmark
| | | | | |
Collapse
|
12
|
Beirão BCB, Ingberman M, Mesa D, Salles GBC, Muniz EC, Caron LF. Effects of aroA deleted E. coli vaccine on intestinal microbiota and mucosal immunity. Comp Immunol Microbiol Infect Dis 2021; 75:101612. [PMID: 33477024 DOI: 10.1016/j.cimid.2021.101612] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 01/10/2021] [Accepted: 01/10/2021] [Indexed: 01/16/2023]
Abstract
E. coli infection of broilers can result in systemic diseases and productivity losses. Use of antimicrobials against this condition is common but other approaches, such as vaccination, are gaining ground. Anecdotal field reports indicate that intestinal health is improved unspecifically following E. coli live vaccination. We hypothesized that the intestine may be an important site for the functionality of the vaccine. Vaccine effects on the intestine were assessed. Spray vaccination induced marked alterations of the caecum microbiota of broilers within 3 days, and this effect gradually waned. However, T cell activation occurred in the spleen, but not in caecal tonsils, and anti-E. coli IgA was concentrated in the respiratory mucosae. Accordingly, IL-6 mRNA was produced in the lungs following immunization. Overall, these data are an initial indication that any vaccine-induced effects on the intestine are greatly associated with the microbiota. However, immunity conferred by vaccination is not primarily induced in gut-associated lymphoid tissues.
Collapse
Affiliation(s)
- Breno C B Beirão
- Imunova Análises Biológicas, Setor de Ciências Biológicas UFPR, Curitiba, PR, 81531-980, Brazil; Universidade Federal do Paraná, Setor de Ciências Biológicas UFPR, Curitiba, 81531-980, Brazil.
| | - Max Ingberman
- Imunova Análises Biológicas, Setor de Ciências Biológicas UFPR, Curitiba, PR, 81531-980, Brazil
| | - Dany Mesa
- Universidade Federal do Paraná, Setor de Ciências Biológicas UFPR, Curitiba, 81531-980, Brazil
| | - Gleidson B C Salles
- Zoetis Indústria de Produtos Veterinários Ltda, São Paulo, SP, 04709-111, Brazil
| | - Eduardo C Muniz
- Zoetis Indústria de Produtos Veterinários Ltda, São Paulo, SP, 04709-111, Brazil
| | - Luiz Felipe Caron
- Universidade Federal do Paraná, Setor de Ciências Biológicas UFPR, Curitiba, 81531-980, Brazil
| |
Collapse
|
13
|
An Assessment of the Level of Protection Against Colibacillosis Conferred by Several Autogenous and/or Commercial Vaccination Programs in Conventional Pullets upon Experimental Challenge. Vet Sci 2020; 7:vetsci7030080. [PMID: 32629910 PMCID: PMC7559755 DOI: 10.3390/vetsci7030080] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 06/15/2020] [Accepted: 06/24/2020] [Indexed: 11/17/2022] Open
Abstract
The prevention of avian colibacillosis has historically been investigated through vaccination, with variable outcomes. Commercial live (attenuated) and inactivated vaccines are reported to have limited efficacy in the context of heterologous challenge. Autogenous vaccination, using field isolates, is widely used, but scarcely documented. Different vaccination programs, including a live commercial vaccine and/or an inactivated autogenous vaccine, were compared for three different avian pathogenic Escherichia coli (APEC) strain (serotypes O78, O18 and O111) challenges. On the pullet farm, four groups of conventional pullets received different vaccination protocols. Group A was kept unvaccinated (control group). Group B was vaccinated three times with a live commercial O78 E. coli vaccine (at one day old, 59 and 110 days of age). Group C was immunized twice (at 79 and 110 days) with a three-valence autogenous vaccine (O78, O18 and O111). Group D was vaccinated first with the commercial vaccine (at one day old and 59 days), then with the autogenous vaccine (110 days). Birds were transferred to the experimental facility at 121 days of age and were challenged 10 days later. In each group, 20 birds were challenged with one of the three APEC strains (O78, O18, O111); in total, 80 birds were challenged by the same strains (20 per group). The recorded outcomes were: mortality rate, macroscopic lesion score in target organs and the bacterial recovery of the challenge strain from bone marrow and pooled organs. When challenged with O78 or O111 strains, birds from groups C and D proved to be significantly better protected, in terms of lesion scoring and bacteriological isolation, than those of groups A and B. With the O18 challenge, only birds of group D presented a statistically significant reduction of their lesion score. To the authors’ knowledge, this is the first report on the efficacy of an immunization program in poultry that combines commercial and autogenous vaccines.
Collapse
|
14
|
Efficacy of Live Attenuated Vaccine and Commercially Available Lectin Against Avian Pathogenic E. coli Infection in Broiler Chickens. Vet Sci 2020; 7:vetsci7020065. [PMID: 32414109 PMCID: PMC7355798 DOI: 10.3390/vetsci7020065] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Revised: 05/06/2020] [Accepted: 05/11/2020] [Indexed: 12/18/2022] Open
Abstract
In this study, the protective efficacy of an E. coli live attenuated vaccine was compared to the preventive administration of lectin preparation before the challenge. Two hundred broiler chicks were divided into eight equal groups. The first group was used as a negative control group. Three groups were vaccinated at day 1 with the avian colibacillosis live vaccine of which one group served as a vaccinated nonchallenged group. Another two groups were treated with lectin product (0.5 mL/L drinking water) for three days before the challenge. The last two groups served as challenge control for either E. coli O78 or O125 strains. The challenge was conducted at three weeks of age with either homologous O78 or heterologous O125E. coli strains, using 0.5 mL/bird of each avian pathogenic E. coli (APEC) strain (~108 colony forming units “CFU”/mL)/subcutaneously. The bodyweight and feed conversion ratios (FCR) were calculated for four weeks. Clinical signs and gross and histopathological lesions were scored at two and seven days post inoculation (dpi). The heart and liver of euthanized chickens at 2 dpi were removed aseptically and homogenized to evaluate pathogenic E. coli colonization. Results showed that live avian colibacillosis vaccine reduced mortalities and APEC colonization in the homologous challenge group but not in the heterologous challenge group. Lectin-treated groups showed 20% and 16% mortality after challenge with E. coli O78 and O125, respectively, and both groups showed performance parameters, clinical signs, and histopathological lesion scores comparable to the negative control group, with variable E. coli colonization of heart and liver. The study demonstrated the efficacy of live attenuated avian colibacillosis vaccine against homologous but not heterologous APEC challenge in broiler chickens. The lectin-containing products can be used as a preventive medication to reduce the clinical impacts of colibacillosis regardless of the challenge strain. Standardization of the evaluation parameters for APEC vaccines is recommended.
Collapse
|
15
|
Christensen H, Nielsen C. Safety of the live Escherichia coli vaccine Poulvac® E. coli in layer parent stock in a field trial. Vet Microbiol 2019; 240:108537. [PMID: 31902490 DOI: 10.1016/j.vetmic.2019.108537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 10/31/2019] [Accepted: 11/28/2019] [Indexed: 10/25/2022]
Abstract
The safety of the live Escherichia coli vaccine Poulvac® E. coli was tested with a flock (10,000) of layer parents aged 30 weeks. Three and 7 days after vaccination, 60 whole unbroken eggs, the egg white and yolk of 60 eggs and 60 cloacal swabs were enriched in MacConkey broth. At both sampling times, 6 out of 60 whole eggs were found positive for coliform bacteria. None of the enriched samples of yolk + egg white were positive for coliform bacteria. Three and seven days after vaccination 44 and 37, respectively out of 60 swabs were positive for coliform bacteria in MacConkey broth. All coliform isolates collected from whole eggs and cloacal swabs were tested in parallel for growth on minimal agar and blood agar to identify the vaccine strain. Some isolates showed reduced growth on minimal agar compared to blood agar and they were tested further with a PCR for the aroA gene mutation and all were found with the wild type version of the gene. Only two isolates did not grow on minimal agar but grew on blood agar and they were tested both with PCR and PFGE. They also showed the wild type version of the aroA gene and their PFGE profile was different from the vaccine strain of Poulvac® E. coli. In conclusion, the Poulvac® E. coli vaccine strain of E. coli was not identified at the detection limit of one CFU on one egg or in the content of one egg or from a cloacal swab of one hen with at least 95 % probability on flock level. The use of the vaccine is safe for hens in lay with lack of survival of the vaccine strain and lack of negative effects on the hens including egg production.
Collapse
Affiliation(s)
- Henrik Christensen
- Department of Veterinary Animal Sciences, University of Copenhagen, Stigbøjlen 4, 1870, Frederiksberg C, Denmark.
| | | |
Collapse
|
16
|
Hoseini Shahidi R, Hashemi Tabar G, Bassami MR, Jamshidi A, Dehghani H. The design and application of a bacterial ghost vaccine to evaluate immune response and defense against avian pathogenic Escherichia coli O2:K1 serotype. Res Vet Sci 2019; 125:153-161. [PMID: 31228739 DOI: 10.1016/j.rvsc.2019.06.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 05/10/2019] [Accepted: 06/03/2019] [Indexed: 12/22/2022]
Abstract
An Escherichia coli (E. coli) O2:K1 bacterial ghost was produced by controlled expression of bacteriophage PhiX 174 lysis gene E. Temperature controlled expression of this gene caused tunnels and holes in the cell wall of E. coli O2:K1 bacterium, leading to loss of cytoplasmic contents. Formation of E. coli O2:K1 ghost was confirmed by scanning electron microscopy and determination of colony forming units. To evaluate the efficiency of this bacterial ghost vaccine to elicit cellular and humoral immune responses, 85 one day old chickens from Ross 308 breed were divided into the following 5 groups; group 1 (non-immunized control), group 2 (vaccine administered by injection of E. coli O2:K1 killed vaccine), group 3 (vaccine administered by injection of E. coli O2:K1 ghost), group 4 (vaccine administered by inhalation of E. coli O2:K1 ghost), and group 5 (neither immunized, nor challenged as negative control). The groups of 2, 3, and 4 were received vaccines at days 7, 14, and 22. Groups 1 to 4 were challenged with the wild type at day 33. Evaluation of post-mortem lesions and immune responses in all groups showed that chicken injected with the killed vaccine and the bacterial ghost had the best protection. These findings suggest that this bacterial ghost has the potential to be used as a poultry colibacillosis vaccine.
Collapse
Affiliation(s)
- Reza Hoseini Shahidi
- Biotechnology Division, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran; The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Gholamreza Hashemi Tabar
- Biotechnology Division, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran; The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran; Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran.
| | - Mohammad Reza Bassami
- Biotechnology Division, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran; The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran; Division of Poultry Diseases, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Abdollah Jamshidi
- Division of Food Hygiene, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Hesam Dehghani
- Biotechnology Division, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran; The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran; Division of Basic Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
| |
Collapse
|
17
|
Hoelzer K, Bielke L, Blake DP, Cox E, Cutting SM, Devriendt B, Erlacher-Vindel E, Goossens E, Karaca K, Lemiere S, Metzner M, Raicek M, Collell Suriñach M, Wong NM, Gay C, Van Immerseel F. Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs. Vet Res 2018; 49:64. [PMID: 30060757 PMCID: PMC6066911 DOI: 10.1186/s13567-018-0560-8] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Accepted: 12/22/2017] [Indexed: 12/25/2022] Open
Abstract
Vaccines and other alternative products can help minimize the need for antibiotics by preventing and controlling infectious diseases in animal populations, and are central to the future success of animal agriculture. To assess scientific advancements related to alternatives to antibiotics and provide actionable strategies to support their development, the United States Department of Agriculture, with support from the World Organisation for Animal Health, organized the second International Symposium on Alternatives to Antibiotics. It focused on six key areas: vaccines; microbial-derived products; non-nutritive phytochemicals; immune-related products; chemicals, enzymes, and innovative drugs; and regulatory pathways to enable the development and licensure of alternatives to antibiotics. This article, part of a two-part series, synthesizes and expands on the expert panel discussions regarding opportunities, challenges and needs for the development of vaccines that may reduce the need for use of antibiotics in animals; new approaches and potential solutions will be discussed in part 2 of this series. Vaccines are widely used to prevent infections in food animals. Various studies have demonstrated that their animal agricultural use can lead to significant reductions in antibiotic consumption, making them promising alternatives to antibiotics. To be widely used in food producing animals, vaccines have to be safe, effective, easy to use, and cost-effective. Many current vaccines fall short in one or more of these respects. Scientific advancements may allow many of these limitations to be overcome, but progress is funding-dependent. Research will have to be prioritized to ensure scarce public resources are dedicated to areas of potentially greatest impact first, and private investments into vaccine development constantly compete with other investment opportunities. Although vaccines have the potential to improve animal health, safeguard agricultural productivity, and reduce antibiotic consumption and resulting resistance risks, targeted research and development investments and concerted efforts by all affected are needed to realize that potential.
Collapse
Affiliation(s)
- Karin Hoelzer
- The Pew Charitable Trusts, 901 E Street NW, Washington, DC, 20004 USA
| | - Lisa Bielke
- Ohio Agriculture and Research Development Center, Animal Sciences, Ohio State University, 202 Gerlaugh Hall, 1680 Madison Ave., Wooster, OH 44691 USA
| | - Damer P. Blake
- Pathobiology and Population Sciences, Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hertfordshire AL9 7TA UK
| | - Eric Cox
- Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salsiburylaan 133, B-9820 Merelbeke, Belgium
| | - Simon M. Cutting
- School of Biological Sciences, Royal Holloway University of London, Egham, Surrey TW20 0EX UK
| | - Bert Devriendt
- Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salsiburylaan 133, B-9820 Merelbeke, Belgium
| | - Elisabeth Erlacher-Vindel
- Science and New Technologies Department, World Organisation for Animal Health (OIE), 12 Rue de Prony, 75017 Paris, France
| | - Evy Goossens
- Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salsiburylaan 133, B-9820 Merelbeke, Belgium
| | - Kemal Karaca
- Elanco Animal Health, 2500 Innovation Way, Greenfield, IN USA
| | | | - Martin Metzner
- RIPAC-LABOR GmbH, Am Mühlenberg 11, 14476 Potsdam, Germany
| | - Margot Raicek
- Science and New Technologies Department, World Organisation for Animal Health (OIE), 12 Rue de Prony, 75017 Paris, France
| | | | - Nora M. Wong
- The Pew Charitable Trusts, 901 E Street NW, Washington, DC, 20004 USA
| | - Cyril Gay
- Office of National Programs, Agricultural Research Service, USDA, Sunnyside Ave, 5601 Beltsville, MD USA
| | - Filip Van Immerseel
- Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salsiburylaan 133, B-9820 Merelbeke, Belgium
| |
Collapse
|
18
|
Efficacy and safety of Poulvac E. coli vaccine in broiler chickens challenged with E. coli serotype O78 and an acute field isolate. ACTA ACUST UNITED AC 2018. [DOI: 10.1007/s00580-018-2784-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Ebrahimi-Nik H, Bassami MR, Mohri M, Rad M, Khan MI. Bacterial ghost of avian pathogenic E. coli (APEC) serotype O78:K80 as a homologous vaccine against avian colibacillosis. PLoS One 2018; 13:e0194888. [PMID: 29566080 PMCID: PMC5864078 DOI: 10.1371/journal.pone.0194888] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Accepted: 03/12/2018] [Indexed: 11/18/2022] Open
Abstract
Avian Colibacillosis is among the major causes of economic loss in the poultry industry worldwide, with a more vivid impact on developing countries. The involvement of several bacteria has made it challenging to develop effective vaccines for this disease, particularly because it is notoriously difficult to make a vaccine that contains all the contributing pathogenic bacteria. Here, we report the design and fabrication of a bacterial ghost (BG) of E. coli O78:K80, which is among the major bacterial serotypes responsible for this disease. The generated ghost is then exploited as a homologous vaccine against Avian Colibacillosis. We demonstrate that hole formation in the cell wall of E. coli O78:K80 can happen properly in optical densities as high as 0.8 compared to the 0.3–0.4 standard for bacteria like E. coli TOP10. This is especially advantageous for mass production of this ghost which is a vital factor in development of any BG-based vaccine. Compared to E. coli TOP10, we faced a great challenge in transforming the wild type bacteria with the E-lysis plasmid which was probably due to higher thickness of the cell wall in O78:K80. This, however, was addressed by treating the cell wall with a different combination of ions.The vaccine was administered to Ross 308 broiler chickens via injection as well as through their respiratory system at a dose of 1010 BGs, repeated 3 times at weekly intervals. Chickens were then challenged with the wild type O78:K80 at a dose of 1011 bacteria together with Infectious Bronchitis H120 vaccine (as immunosuppressant) one week after the last immunization. Air sac lesions were significantly reduced in BG vaccinated groups in comparison with the control group. The levels of IFNγ, IgA and IgY were measured in the serum of immunized chickens as an indication of immune response and were compared with those of the chickens vaccinated with killed bacteria. The results show that O78:K80 BG can be used as an efficient homologous vaccine against Colibacillosis disease in poultry. We expect our findings can serve as the starting point for designing more sophisticated vaccines that contain all three major pathogenic bacteria involved in avian Colibacillosis.
Collapse
Affiliation(s)
- Hakimeh Ebrahimi-Nik
- Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Mohammad Reza Bassami
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Mehrdad Mohri
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
- * E-mail:
| | - Mehrnaz Rad
- Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Mazhar I. Khan
- Department of Pathobiology and Veterinary Science, University of Connecticut, Storrs, CT, United States of America
| |
Collapse
|
20
|
Uotani Y, Kitahara R, Imai T, Tsutsumi N, Sasakawa C, Nagai S, Nagano T. Efficacy of an avian colibacillosis live vaccine for layer breeder in Japan. J Vet Med Sci 2017; 79:1215-1219. [PMID: 28603216 PMCID: PMC5559366 DOI: 10.1292/jvms.17-0189] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Colibacillosis is one of an economically significant disease in the poultry industry, especially for meat breed chickens. Recently it has become a serious problem for layer especially when the birds start laying and also at the later stage of laying. In Japan, the productivity of field laying hens improved when the Δcrp avian colibacillosis live vaccine (“Gall N tect CBL”) was used. The survival rate and egg laying rate increased during almost all of the laying period when compared with the control group. The improvement in productivity was clearly demonstrated by comparing the number of eggs laid per day. The use of an avian colibacillosis live vaccine proved to be cost-effective in laying hens.
Collapse
Affiliation(s)
- Yusuke Uotani
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan
| | - Rie Kitahara
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan
| | - Takahiko Imai
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan
| | - Nobuyuki Tsutsumi
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan
| | - Chihiro Sasakawa
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan.,Medical Mycology Research Center, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8673 Japan
| | - Shinya Nagai
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan
| | - Tetsuji Nagano
- Nippon Institute for Biological Science, 9-2221-1 Shinmachi, Ome, Tokyo 198-0024, Japan
| |
Collapse
|
21
|
Li L, Thøfner I, Christensen JP, Ronco T, Pedersen K, Olsen RH. Evaluation of the efficacy of an autogenous Escherichia coli vaccine in broiler breeders. Avian Pathol 2017; 46:300-308. [PMID: 27982712 DOI: 10.1080/03079457.2016.1267857] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
In poultry production Escherichia coli autogenous vaccines are often used. However, the efficacy of autogenous E. coli vaccinations has not been evaluated experimentally in chickens after start of lay. The aim of the present study was to evaluate the protective effect of an autogenous E. coli vaccine in broiler breeders. Three groups of 28-week-old broiler breeders (unvaccinated, vaccinated once and twice, respectively) were challenged with a homologous E. coli strain (same strain as included in the vaccine) or a heterologous challenge strain in an experimental ascending model. The clinical outcome was most pronounced in the unvaccinated group; however, the vast majority of chickens in the vaccinated groups had severe pathological manifestations similar to findings in the unvaccinated group after challenge with a homologous as well as a heterologous E. coli strain. Although significant titre rises in IgY antibodies were observed in the twice vaccinated group, antibodies did not confer significant protection in terms of pathological impact. Neither could transfer of maternal-derived antibodies to offspring be demonstrated. In conclusion, with the use of the present model for ascending infection, significant protection of an autogenous E. coli vaccine against neither a homologous nor a heterologous E. coli challenge could not be documented.
Collapse
Affiliation(s)
- Lili Li
- a College of Light Industry and Food Sciences , South China University of Technology , Guangzhou , Guangdong , People's Republic of China
| | - Ida Thøfner
- b Department of Veterinary Disease Biology , University of Copenhagen , Frederiksberg , Denmark
| | - Jens Peter Christensen
- b Department of Veterinary Disease Biology , University of Copenhagen , Frederiksberg , Denmark
| | - Troels Ronco
- c National Veterinary Institute , Technical University of Denmark , Frederiksberg , Denmark
| | - Karl Pedersen
- c National Veterinary Institute , Technical University of Denmark , Frederiksberg , Denmark
| | - Rikke H Olsen
- b Department of Veterinary Disease Biology , University of Copenhagen , Frederiksberg , Denmark
| |
Collapse
|
22
|
Deletion of luxS further attenuates the virulence of the avian pathogenic Escherichia coli aroA mutant. Microb Pathog 2015; 88:39-47. [PMID: 26271577 DOI: 10.1016/j.micpath.2015.08.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Revised: 07/14/2015] [Accepted: 08/05/2015] [Indexed: 12/29/2022]
Abstract
In this study, an aroA-deletion avian pathogenic Escherichia coli (APEC) mutant (strain DE17ΔaroA) and aroA and luxS double deletion APEC mutant (strain DE17ΔluxSΔaroA) were constructed from the APEC DE17 strain. The results showed that as compared to DE17ΔaroA, the virulence of DE17ΔluxSΔaroA was further attenuated by 200- and 31.7-fold, respectively, in ducklings based on the 50% lethal dose. The adherence and invasion abilities of DE17ΔluxSΔaroA and DE17ΔaroA were reduced by 36.5%/42.5% and 25.8%/29.3%, respectively, as compared to the wild-type strain DE17 (p < 0.05 and 0.01, respectively). Furthermore, in vivo studies showed that the bacterial loads of DE17ΔluxSΔaroA were reduced by 8400- and 11,333-fold in the spleen and blood of infected birds, respectively, while those of DE17ΔaroA were reduced by 743- and 1000-fold, respectively, as compared to the wild-type strain DE17. Histopathological analysis showed both that the mutants were associated with reduced pathological changes in the liver, spleen, and kidney of ducklings, and changes in DE17ΔluxSΔaroA-infected ducklings were reduced to a greater degree than those infected with DE17ΔaroA. Real-time polymerase chain reaction analysis further demonstrated that the mRNA levels of virulence-related genes (i.e., tsh, ompA, vat, iucD, pfs, fyuA, and fimC) were significantly decreased in DE17ΔaroA, especially in DE17ΔluxSΔaroA, as compared to DE17 (p < 0.05). In addition, the deletion of aroA or the double deletion of aroA and luxS reduced bacterial motility. To evaluate the potential use of DE17ΔluxSΔaroA as a vaccine candidate, 50 7-day-old ducklings were divided randomly into five groups of ten each for the experiment. The results showed that the ducklings immunized with inactivated DE17, DE17ΔluxS, DE17ΔaroA, and DE17ΔluxSΔaroA were 70.0%, 70.0%, 70.0, and 80.0% protected, respectively, after challenge with strain APEC DE17. The results of this study suggest that the double deletion of luxS and aroA attenuated APEC pathogenicity and DE17ΔluxSΔaroA was more appropriate for development of a future vaccine against avian colibacillosis than DE17ΔaroA.
Collapse
|
23
|
Sadeyen JR, Wu Z, Davies H, van Diemen PM, Milicic A, La Ragione RM, Kaiser P, Stevens MP, Dziva F. Immune responses associated with homologous protection conferred by commercial vaccines for control of avian pathogenic Escherichia coli in turkeys. Vet Res 2015; 46:5. [PMID: 25613193 PMCID: PMC4304773 DOI: 10.1186/s13567-014-0132-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Accepted: 12/04/2014] [Indexed: 11/10/2022] Open
Abstract
Avian pathogenic Escherichia coli (APEC) infections are a serious impediment to sustainable poultry production worldwide. Licensed vaccines are available, but the immunological basis of protection is ill-defined and a need exists to extend cross-serotype efficacy. Here, we analysed innate and adaptive responses induced by commercial vaccines in turkeys. Both a live-attenuated APEC O78 ΔaroA vaccine (Poulvac® E. coli) and a formalin-inactivated APEC O78 bacterin conferred significant protection against homologous intra-airsac challenge in a model of acute colibacillosis. Analysis of expression levels of signature cytokine mRNAs indicated that both vaccines induced a predominantly Th2 response in the spleen. Both vaccines resulted in increased levels of serum O78-specific IgY detected by ELISA and significant splenocyte recall responses to soluble APEC antigens at post-vaccination and post-challenge periods. Supplementing a non-adjuvanted inactivated vaccine with Th2-biasing (Titermax® Gold or aluminium hydroxide) or Th1-biasing (CASAC or CpG motifs) adjuvants, suggested that Th2-biasing adjuvants may give more protection. However, all adjuvants tested augmented humoral responses and protection relative to controls. Our data highlight the importance of both cell-mediated and antibody responses in APEC vaccine-mediated protection toward the control of a key avian endemic disease.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Francis Dziva
- Avian Infectious Diseases Programme, The Pirbright Institute, Compton RG20 7NN, Berkshire, UK.
| |
Collapse
|